Form 4: Sutro Biopharma Executive Reports Stock Transaction
Insider Transaction (Form 4)
Hans-Peter Gerber, CHIEF SCIENTIFIC OFFICER of Sutro Biopharma, Inc., reported multiple transactions in common stock on September 18, 2026.
Summary
- Option exercise/conversion: acquired 3,750 Common Stock on September 18, 2026; holds 13,712 after (Direct).
- Tax/exercise-price withholding: disposed of 1,345 Common Stock at $15.34 ($20,632) on September 18, 2026; holds 12,367 after (Direct).
- Option exercise/conversion: disposed of 3,750 Restricted Stock Units (RSUs) on September 18, 2026; holds 3,750 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Hans-Peter Gerber — Officer (CHIEF SCIENTIFIC OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Option exercise/conversion | Common Stock | 3,750 | — | — | 13,712 |
| 2026-09-18 | Tax/exercise-price withholding | Common Stock | 1,345 | $15 | $20.6K | 12,367 |
| 2026-09-18 | Option exercise/conversion | Restricted Stock Units (RSUs) | 3,750 | — | — | 3,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Option exercise/conversion (3,750 shares) |
| 2026-09-18 | Tax/exercise-price withholding (1,345 shares) |
| 2026-09-18 | Option exercise/conversion (3,750 shares) |
Keywords
insider transaction, Form 4, STRO, SUTRO BIOPHARMA, INC., neutral, Hans-Peter Gerber
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.